

PRESS RELEASE

STRATEC'S ANNUAL GENERAL MEETING APPROVES DISTRIBUTION OF A DIVIDEND OF € 0.84 PER SHARE

Birkenfeld, June 8, 2020

At today's Annual General Meeting of STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX) which, due to the COVID-19 pandemic, was held on a virtual basis for the first time, the company's shareholders approved all agenda items submitted for resolution with clear majorities. Overall, 81.8% of the company's share capital was represented at the virtual Annual General Meeting.

As proposed, STRATEC will be distributing a dividend of € 0.84 per share to its shareholders for the past 2019 financial year (previous year: € 0.82). The distribution total amounts to € 10.1 million and will be paid out to shareholders via their depositing banks on June 12, 2020. This represents the sixteenth consecutive increase in the dividend since payment of the first dividend in 2004.

Shareholders also approved the actions of the Board of Management and the Supervisory Board and elected Ebner Stolz GmbH & Co. KG, Stuttgart, as auditor for the 2020 financial year. The Annual General Meeting also renewed its approval for authorized and conditional capital, as well as the authorization to acquire and dispose of treasury stock.

Rather than holding a general debate, shareholders had the opportunity to submit questions in advance of the Annual General Meeting. All questions were addressed during the meeting.

Further information about the Annual General Meeting can be found at www.strattec.com/agm, where details of voting results have also been published.

ABOUT STRATEC

STRATEC SE (www.strattec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:

STRATEC SE

Jan Keppeler | Investor Relations & Corporate Communications

Tel: +49 7082 7916-6515

Fax: +49 7082 7916-9190

ir@stratec.com

www.stratec.com